Sure. So, Saharsh, we are in the peptide capability from last 16, 18 years. We are working on that. We have developed several molecules from basic to complex range. Now we are putting the capacity also. So from an investor's point of view, seeing the company from 5 years and more than 5 years down the line, this category in itself has the potential to create one more Neuland in terms of numbers? I don't want to know the name of the specific molecule, specific capability. Just what the company is building and how should investor look at it from next 5 years perspective? Is it fair to assume that this category in itself has a potential to create one more Neuland in terms of numbers?
Questions across 6 calls
Harshit Dhoot
Dymon Asia Capital
Neuland Laboratories Limited
Saharsh, keeping in mind the base of FY 24. And as you also know that our quarterly numbers are very lumpy. So if we see from 3 to 5 years perspective, taking in mind FY24 base, how should we see the growth and margin trajectory of the Neuland going forward? Is it improving from there onwards and other part and are we entering into the multi fold growth period from next 5 years perspective, the kind of pipeline that we have and the kind of shipments that you have discussed that now we are shipping around INR50 crores, INR100 crores of the individual segments?
So when a business starts to pick up, then we see a significant growth path than the growth margin and then the business matures. And keeping in mind, the big sector tailwind, your investments into the peptides, new CMS m olecules that we are witnessing, so where are we positioned in terms of the business cycle, i n the starting significant growth phase or the second or the other one?
Divi's Laboratories Limited
Congratulations on the good set of numbers. A couple of questions from my side. Our gross asset turnover ratio in FY '25 was 1.19 and we are incurring the dedicated capex . And with the revenue visibility from these 3 capex and the pipeline in the CS segment, can we expect going back to the 1.5 to 1.6 kind of range in the next 4, 5 years?
Yes, yes, sorry. So my question was that, ma'am, our gross asset turnover ratio was 1.2 in FY '25. And with the visibility of the revenues from the dedicated capex and multiple products in the pipeline in the CS segment, -- can it go back to the historical high level of 1.5 to 1.8 level in next 4, 5 years? How should we understand the going forward, the revenue trajectory?
Glenmark Pharmaceuticals Limited
One question from my side on domestic sales. We have clocked a very good performance during the quarter at clocking at around INR1300 crores out of sales. So is it fair to assume that I think is normalized and this run rate is sustainable in the domestic business?
Just a couple of questions from my side. Given the ANDAs and executive order in the U.S., have you told by the global pharma that valuations for all the originated products might recalibrate. So any update on this, sir?
Okay. Nothing on the products like -- the companies like IGI are working on that, something like ISB 2001 that we are working on?
Mankind Pharma Limited
Sir, you said organic business growth is at 8% Y-o-Y, right?
Our organic domestic business grew 8% Y-o-Y, right? That's what you said.